ESC Professional Premium Access

We all know A and B, but what about C? Exploring the management of modifiable risk factors in patients with atrial fibrillation.

Congress Session

About the speaker

Miss Dominique Valerie Mabelle Verhaert

Radboud University Medical Center, Nijmegen (Netherlands (The))
0 follower

6 more presentations in this session

Associations of soluble fms-like tyrosine kinase-1 with cardiovascular events and stroke in patients with atrial fibrillation and suspected or known coronary artery disease: The EXCEED-J Study

Speaker: Doctor K. Hasegawa (Kyoto, JP)

Thumbnail

Prediction of atrial fibrillation in patients with embolic stroke with undetermined source using electrocardiogram deep learning algorithm and clinical risk factors

Speaker: Associate Professor J. Lee (Seongnam, KR)

Thumbnail

Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network

Speaker: Doctor K. Arps (Durham, US)

Thumbnail

The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe

Speaker: Doctor T. de Vries (Amsterdam, NL)

Thumbnail

Should we initiate oral anticoagulants for patients with atrial fibrillation staying well without oral anticoagulants for years?

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Access the full session

Stroke prevention in atrial fibrillation

Speakers: Miss D. Verhaert, Doctor K. Hasegawa, Associate Professor J. Lee, Doctor K. Arps, Doctor T. de Vries...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk